Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia

References

• Swerdlow SH, Cook JR, Sohani AR, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL editors WHO classification of TUMOURS OF HEMATOPOIETIC AND LYMPHOID TISSUES. Lyon: IARC; 2017. p. 232–235.
   Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012; 367(9)826–833.
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013 Aug 15;122(7):1222–1232.
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014 Mar 13;123(11):1637–1646.•• This manuscript describes the important role that CXCR4 mutations play in the development and proliferation of WM.
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Venet-Caillault A, et al. Genomic Landscape of CXCR4 mutations in Waldenström Macroglobulinemia. Clin Cancer Res. 2016 Mar 15;22(6):1480–1488.
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia. Leukemia. 2015 Jan;29(1):169–176.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Moreno DF, Arbelaez MI, et al. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: a systematic review. Expert Rev Hematol. 2019 Oct;1210:873–881.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Xu L, Gustine JN, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 Nov;187(3):356–363.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenström Macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020 Apr 10;38(11):1198–1208.
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014 May 1;123(18):2791–2796.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 Feb;180(3):374–380.
   PubMed Web of Science ®Google Scholar
• Kofides A, Hunter ZR, Xu L, et al. Diagnostic next-generation sequencing frequently fails to detect MYD88(L265P) in Waldenstrom Macroglobulinemia. Hemasphere. 2021 Aug;5(8):e624.
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14;121(11):2051–2058.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 1;31(1):88–94.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenstrom Macroglobulinemia:The aspen study. Blood. 2020Jul30; 136(18)2038–2050.
   PubMed Web of Science ®Google Scholar
• Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2021 Feb 20;39(6):565–575.
   PubMed Web of Science ®Google Scholar
• Trotman J, Buske C, Tedeschi A, et al. Single-agent ibrutinib for rituximab-refractory Waldenstrom Macroglobulinemia: final analysis of the substudy of the phase III innovate(TM) trial. Clin Cancer Res. 2021 Nov 1;27(21):5793–5800.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2021 Sep 16;36(2):532–539.
   PubMed Web of Science ®Google Scholar
• Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom’s Macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2021 Oct 4; JCO2100838. DOI:https://doi.org/10.1200/JCO.21.00838.
   Google Scholar
• Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020 Feb;72:e112–e121.
   PubMed Web of Science ®Google Scholar
• Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up. Blood. 2020 Oct 29;136(18):2027–2037.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom Macroglobulinemia. J Clin Oncol. 2018; 36(27)2755–2761.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399–2410.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):241–250.
   PubMed Web of Science ®Google Scholar
• Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom’s Macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022 Jan 1;40(1):52–62.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):323–332.
   PubMed Web of Science ®Google Scholar
• Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132(Supplement 1):1871.
   PubMedGoogle Scholar
• Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12;134(11):851–859.
   PubMed Web of Science ®Google Scholar
• Ou YC, Tang Z, Novotny W, et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma. 2021 Nov;62(11):2612–2624.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Sanz RG, Lee HP, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020 Dec 8;4(23):6009–6018.
   PubMed Web of Science ®Google Scholar
• FDA approves zanubrutinib for Waldenström’s macroglobulinemia [website]. [cited 2021 Dec 23]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Version 1.2022. Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma. [cited 2022 Jan 23]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf
   Google Scholar
• Gustine JN, Xu L, Yang G, et al. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstrom macroglobulinaemia. Br J Haematol. 2021 Aug;194(4):730–733.
   PubMed Web of Science ®Google Scholar
• FI SM, Levy MY, Porter R, et al. Phase 2 study of Zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies. Blood. 2021;138:1410.
   Google Scholar
• Wong J, Cher L, Griffiths J, et al. Efficacy of zanubrutinib in the treatment of bing-neel syndrome. Hemasphere. 2018 Dec;2(6):e155.
   PubMed Web of Science ®Google Scholar
• Munakata W, Ando K, Hatake K, et al. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019 May;110(5):1686–1694.
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom’s macroglobulinemia. Cancer Sci. 2020 Sep;111(9):3327–3337.
   PubMed Web of Science ®Google Scholar
• Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016 Jan 28;127(4):411–419.
   PubMed Web of Science ®Google Scholar
• Zhou D, Jin J, Fu Z, et al. Efficacy and safety of orelabrutinib in relapsed/refractory Waldenstrom’s Macroglobulinemia patients. Blood. 2021;138(Supplement 1):46.
   Google Scholar
• Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017 May 1;35(13):1437–1443.
   PubMed Web of Science ®Google Scholar
• Xu L, Tsakmaklis N, Yang G, et al. Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. Blood. 2017 May 4;129(18):2519–2525.
   PubMed Web of Science ®Google Scholar
• Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6;397(10277):892–901.
   PubMed Web of Science ®Google Scholar
• Wang E, Mi X, Thompson MC, et al. Mechanisms of resistance to noncovalent bruton’s tyrosine kinase inhibitors. N Engl J Med. 2022 Feb 24;386(8):735–743.
   PubMed Web of Science ®Google Scholar
• Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018 Aug;97(8):1417–1425.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström’s Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133–135.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s Macroglobulinemia: results of WMCTG trial 03-248. Clin Cancer Res. 2007 Jun 1;13(11):3320–3325.
   PubMed Web of Science ®Google Scholar
• Gustine JN, Sarosiek S, Flynn CA, et al. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2021 Jun 24. DOI:https://doi.org/10.3324/haematol.2021.279112.
   Google Scholar